Literature DB >> 9178910

Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25.

S J Plummer1, L Adams, J A Simmons, G Casey.   

Abstract

Chromosome 17 is one of the most frequently altered chromosomes in malignant breast cancer. At least four genes implicated in breast cancer reside on chromosome 17 (p53, 17p13; Her-2/neu/ERBB2, 17q12; BRCA1, 17q21; and nm23, 17q22). In addition, allelic imbalance has been described for at least five regions of chromosome 17. We have previously shown that the introduction of a normal human chromosome 17 into the breast cancer cell line MCF7 by microcell mediated chromosome transfer (MMCT) results in the in vitro growth arrest of these cells within 8 weeks, suggesting the presence of a growth suppressor on chromosome 17. Additionally, we have shown that the tumor suppressor gene p53 is not responsible for this phenotype, as it is wild type in MCF7 cells, and overexpression has no effect on either the in vitro or in vivo growth of these cells. We have further localized this growth suppressor gene to 17q24-q25 by transfer of chromosome 17 hybrids containing defined deletions. Whereas transfer of hybrids that contained an intact 17q (delta43/A9 and delta26/A9) resulted in growth arrest, two hybrids with overlapping deletions at 17q24-q25, had no effect on growth of MCF7 cells. Molecular analyses revealed that 50/70 (71%) of the resulting delta2/MCF7 or delta624/MCF7 MMCT clones retained an intact introduced chromosome 17. In contrast, only 8/34 (24%) of delta43/MCF7 revertants (deleted for 17p13.1-pter) which escaped growth arrest showed no breakage of the introduced chromosome 17. We did not observe a preferential loss of an intragenic BRCA1 marker in the MMCT hybrids, excluding BRCA1 as the gene responsible for this growth arrest phenotype. These data therefore implicate a new growth suppressor gene involved in breast cancer that is localized to chromosome 17q24-q25.

Entities:  

Mesh:

Year:  1997        PMID: 9178910     DOI: 10.1038/sj.onc.1201073

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

1.  NHERF1/EBP50 in Breast Cancer: Clinical Perspectives.

Authors:  Antonia Bellizzi; Andrea Malfettone; Rosa A Cardone; Anita Mangia
Journal:  Breast Care (Basel)       Date:  2010-04-09       Impact factor: 2.860

Review 2.  Pathophysiological role of ion channels and transporters in HER2-positive breast cancer.

Authors:  Zhengxing Zhou; Chengmin Zhang; Zhiyuan Ma; Hu Wang; Biguang Tuo; Xiaoming Cheng; Xuemei Liu; Taolang Li
Journal:  Cancer Gene Ther       Date:  2022-01-07       Impact factor: 5.854

3.  Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.

Authors:  J Edwards; P Duncan; J J Going; K M Grigor; A D Watters; J M Bartlett
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

4.  p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.

Authors:  M Müller; S Wilder; D Bannasch; D Israeli; K Lehlbach; M Li-Weber; S L Friedman; P R Galle; W Stremmel; M Oren; P H Krammer
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.